Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients

  • Choi, Jaeyoung (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Ben (Department of Pediatrics, School of Medicine, Kyungpook National University) ;
  • Kim, Min-Ji (Biostatistics and Clinical Epidemiology Center, Samsung Medical Center) ;
  • Sohn, Insuk (Biostatistics and Clinical Epidemiology Center, Samsung Medical Center) ;
  • Lee, Hae Jeong (Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Choe, Yon Ho (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2017.07.04
  • Accepted : 2017.09.22
  • Published : 2018.05.15
⟨ Previous Next ⟩

Abstract

Background/Aims: Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn's disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons. Methods: This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups. Results: The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1-2 (p=0.016). Conclusions: The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.

Keywords

References

  1. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-1207. https://doi.org/10.1016/j.crohns.2014.04.005
  2. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 Suppl 1:i36-i58. https://doi.org/10.1136/gut.2005.081950c
  3. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-873. https://doi.org/10.1053/j.gastro.2006.12.003
  4. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-374.e2. https://doi.org/10.1053/j.gastro.2012.04.046
  5. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-667. https://doi.org/10.1016/S0140-6736(08)60304-9
  6. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-1834. https://doi.org/10.1016/S0140-6736(15)00068-9
  7. Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab “Top-Down” strategy is superior to “Step-Up” in maintaining long-term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:737-743. https://doi.org/10.1097/MPG.0000000000000711
  8. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-347. https://doi.org/10.1016/j.dld.2003.12.014
  9. Mamula P, Telega GW, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002;97:2005-2010. https://doi.org/10.1111/j.1572-0241.2002.05915.x
  10. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014;146:383-391. https://doi.org/10.1053/j.gastro.2013.10.027
  11. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011;17:2144-2152. https://doi.org/10.1002/ibd.21615
  12. Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1177-1186. https://doi.org/10.1097/MIB.0000000000000083
  13. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011;27:651-662. https://doi.org/10.1185/03007995.2010.547575
  14. Cameron FL, Altowati MA, Rogers P, et al. Disease status and pubertal stage predict improved growth in antitumor necrosis factor therapy for pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2017;64:47-55. https://doi.org/10.1097/MPG.0000000000001379
  15. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.
  16. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-421. https://doi.org/10.1097/01.mpg.0000183350.46795.42
  17. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-1321. https://doi.org/10.1002/ibd.21493
  18. Lee MN, Kang B, Choi SY, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis 2015;21:1054-1062. https://doi.org/10.1097/MIB.0000000000000347
  19. Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal healing in paediatric patients with moderate-to-severe Luminal Crohn's disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis 2016;10:1279-1286. https://doi.org/10.1093/ecco-jcc/jjw086
  20. Korea Center for Disease Control and Prevention; The Korean Pediatric Society; The Committee for the Development of Growth Standard for Korean Children and Adolescents. 2007 Korean Children and Adolescents Growth Standard (commentary for the development of 2007 growth chart) [Internet]. Seoul: Division of Chronic Disease Surveillance; c2007 [cited 2017 March 2]. Available from: http://cdc.go.kr/CDC/notice/CdcKrInfo0201.jsp?menuIds=HOME001-MNU1154-MNU0005-MNU1889?cid=1235.
  21. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993;34:939-943. https://doi.org/10.1136/gut.34.7.939
  22. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993;105:681-691. https://doi.org/10.1016/0016-5085(93)90883-E
  23. Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 2002;58 Suppl 1:7-10.
  24. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000;46:694-700.
  25. Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981;80:10-15.
  26. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-1264. https://doi.org/10.1136/gutjnl-2013-305259
  27. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48:257-267. https://doi.org/10.1097/MPG.0b013e31818cf555
  28. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.e1. https://doi.org/10.1016/j.cgh.2010.09.016
  29. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-688.e1. https://doi.org/10.1053/j.gastro.2013.11.024
  30. Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2015;21:951-961. https://doi.org/10.1097/MIB.0000000000000245
  31. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205-210. https://doi.org/10.1203/00006450-200302000-00002
  32. Chun JY, Kang B, Lee YM, Lee SY, Kim MJ, Choe YH. Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients. Pediatr Gastroenterol Hepatol Nutr 2013;16:171-177. https://doi.org/10.5223/pghn.2013.16.3.171

Cited by

  1. The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease vol.12, pp.3, 2018, https://doi.org/10.5009/gnl18112
  2. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target vol.21, pp.1, 2018, https://doi.org/10.5223/pghn.2018.21.1.1
  3. A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT : vol.41, pp.4, 2018, https://doi.org/10.1097/sga.0000000000000401
  4. Updates in Healthcare Maintenance and Monitoring of Children with Inflammatory Bowel Disease in the Era of Biologic Therapies vol.5, pp.4, 2019, https://doi.org/10.1007/s40746-019-00181-4
  5. Current Trends in the Treatment of Systemic Lupus Erythematosus vol.26, pp.22, 2018, https://doi.org/10.2174/1381612826666200211122633
  6. Precision medicine for pediatric inflammatory bowel disease: a perspective vol.4, pp.2, 2020, https://doi.org/10.23838/pfm.2020.00058
  7. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease vol.15, pp.4, 2018, https://doi.org/10.5009/gnl20134